The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

PURPOSE: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Peirce, Susan K., Findley, Harry W., Prince, Chengyu, Dasgupta, Anindya, Cooper, Todd, Durden, Donald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143317/
https://www.ncbi.nlm.nih.gov/pubmed/20972874
http://dx.doi.org/10.1007/s00280-010-1486-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143317/
https://www.ncbi.nlm.nih.gov/pubmed/20972874
http://dx.doi.org/10.1007/s00280-010-1486-7

Ejemplares similares